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Abstract  
Aims Diagnosis and treatment of fibromyalgia syndrome (FMS) currently focuses on 
the experience of widespread pain. However, the symptom experience described by 
patients with FMS in clinical practice is far more diverse. This study aims identify the 
most common and severe symptoms in female patients diagnosed with FMS.  
Methods This study interviewed 56 patients diagnosed with fibromyalgia syndrome 
about their symptoms using the Clinical Interview Schedule – Revised. 
Results The most frequent and disabling symptoms reported by participants were 
fatigue, sleep disturbance and cognitive difficulties. 
Conclusions These findings highlight the need for a range of symptoms to be 
considered in the assessment and treatment of FMS to help improve patient outcomes.  
Fibromyalgia syndrome (FMS) is recognised as one of the most common conditions 
in patients with musculoskeletal pain.1,2 It is a complex disorder that affects women 
more than men.3,4 The pathophysiology of FMS requires further research. Emerging 
evidence suggests that there are abnormalities of both peripheral and central nervous 
system resulting in augmented sensory processing in the brain and decreased central 
nervous system inhibition of peripheral nociceptive signalling.5 Genetic and 
environmental factors have also been linked to an increased risk of developing 
FMS.6,7 
FMS is associated with significantly high societal and health care costs8-12 with 
patients making more than double the number of visits to health care services than 
non-FMS controls and revealing higher levels of medication use.10 This increased 
level of health care use has been found to remain stable over the course of the illness 
(despite an initial decrease in service utilisation during the year following 
diagnosis).13  
FMS is also associated with high indirect costs to society, as many people with FMS 
are forced to leave employment, reduce their working hours or have increased 
absence from work as a result of their FMS symptoms.12,14-16 In a general population 
study conducted in New Zealand (NZ), the prevalence of FMS has been estimated to 
be 1.1% in Maori and 1.5% in NZ European,17 although internationally prevalence 
rates vary considerably, between 0.7% to 11%.13,15,18–20 
FMS is diagnosed based on the experience of widespread chronic pain and tender 
points, however, according to the American College of Rheumatology Criteria,3 many 
people with FMS and clinicians report a number of associated psychological and 
physical symptoms including; mood disturbance,21–23 fatigue, sleep disturbance, 
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morning stiffness, paresthesias, headache, Raynaud’s phenomenon and irritable bowel 
symptoms.18,24,25  
The occurrence of symptoms, in addition to pain may contribute to the significantly 
lower quality of life and reduced physical functioning found in this population in 
comparison to other chronic pain conditions, such as rheumatoid arthritis.26 
Pharmacotherapy has demonstrated effective symptom reduction in FMS, although 
the side effects can limit tolerability27–32. It is widely acknowledged that medication 
should be integrated into an individualised treatment regime including exercise and 
psychological therapy (such as cognitive behavioural therapy).33–35 
As the symptom profile of FMS is so diverse it is difficult for practitioners to identify 
the symptoms most likely to impact on patients with FMS to help to guide their 
treatment. Research exploring the nature and extent of diagnosed psychological 
disorders from a review of studies completed into FMS has revealed higher levels of 
anxiety and depressive disorders in people within FMS in comparison to controls36 
However further research is needed to explore the nature and severity of the common 
symptoms that people with FMS may experience, particularly in NZ.  
To develop appropriate health care provision that meets the needs of patients, a clear 
understanding of the symptom experience is essential. This study aims identify the 
most common and severe symptoms in female patients diagnosed with FMS and to 
compare the findings in relation to community norms.  
Methods 
An interview was conducted to explore the frequency and severity of common 
symptoms using a Structured Clinical Interview Schedule.  
Participants—Participants were included in the study if; 1) they had been diagnosed 
with FMS by a GP or consultant; 2) FMS was reported to be their primary diagnosis; 
3) they were over 18 years of age; 4) they were female (as the population of FMS 
predominantly affects females this enabled comparison of the findings with a general 
population female sample). Participants were excluded if; 1) they are unable to speak 
or understand English or; 2) they have a serious medical condition that is likely to 
affect the findings of the study, such as cancer or a specific diagnosed psychiatric 
disorder (such as schizophrenia, anxiety or depressive disorders).  
Advertisements for the study were placed in patient newsletters distributed through 
Arthritis New Zealand and patient support groups for people with FMS across New 
Zealand. Patients who contacted the research team in response to the advertisements 
were sent an information sheet explaining the study and a consent form.  
Participants were given the opportunity to talk to a member of the research team 
before they were asked to sign and return the consent in the prepaid envelope 
provided. Participants were only able to participate on receipt of the signed consent 
form. 
Assessments—Information on age, gender, ethnicity, co morbid medical diagnoses, 
FMS symptom duration and medication use were recorded. The Structured Clinical 
Interview Schedule (CIS-R)37 was then administered to all participants via the 
telephone or in person.  
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Two modes of administration were provided to enable those who were unable to 
travel to attend an in person interview to take part and also to provide the option of an 
in person interview for those who preferred this approach. The CIS-R has been 
validated for use by telephone and face to face presentation with no evidence of 
difference in outcomes found by the different modes of administration.38 
The CIS-R is a standardised assessment that explores the occurrence of a wide range 
of symptoms in patients with physical health conditions.39 The interview comprises of 
14 sections (somatic symptoms, fatigue, concentration difficulties, sleep problems, 
irritability, worry about physical health, depression, depressive ideas, worry, anxiety, 
phobias, panic attacks, compulsions and obsessions) and asks patients about the 
existence of each symptom over the past month.  
If the symptom is reported to have occurred in the past month, a more detailed 
assessment is completed to establish the frequency, duration, severity and time since 
onset and is intended for use by non-professional interviewers. Symptom sub-scales 
are scored between 0 to 4 (the depressive ideas subscale is scored between 0 to 5) 
with scores ≥2 indicating the symptom is frequent and severe. A total scale score is 
also calculated (0–57) with scores of ≥12 reflecting more severe symptoms. Norms 
are available for a female sample of (N=4728) collected from a household survey of 
people aged 16 to 74 years.40  
The total telephone assessment took approximately 40 minutes to complete, with high 
scores indicative of greater symptom severity.  
Data analysis—Frequencies, means and standard deviations (or medians and 
interquartile ranges if data did not meet parametric assumptions) were used to 
describe the characteristics of the participant sample. Descriptive analysis was 
completed to state the nature, frequency, duration, severity and symptoms duration of 
the 14 symptom domains explored in the CIS-R for the FMS participants. Adjusted 
odds ratios (95% confidence intervals) were calculated comparing the frequency of 
domain scores of ≥2 (indicating severe symptom experience) on each of the 14 
symptom domains in comparison to the CIS-R community norms.  
A priori power calculation for χ2 goodness of fit test using G*power 3.1 based on a 
medium effect size of 0.4, power 0.8 and alpha level of 0.05 (df 1) revealed that a 
minimum sample of N=50 would be required to detect significant differences between 
the FMS population and community norms. 
Results 
Sixty-one participants contacted the research team in response to the advertisement 
and were sent an information pack in the post. Fifty eight participants (95%) returned 
the signed consent form, and were screened for eligibility. One participant was 
excluded as they had not been diagnosed by a clinician or consultant and one 
participant was no longer contactable, consequently fifty six female participants 
completed the interview either by telephone (n=52) or face to face (N=4). 
Characteristics of the FMS participants are described in Table 1. 
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Table1. Participant characteristics (N=56) 
 
Characteristic Value 
Age (mean, SD) 
Age range 
56.89 years (13.99) 
20–85 years 
Symptom duration (mean, SD) 15.84 years (13.32) 
Medication use 
Yes 
No 
 
51 (91.1%) 
5 (8.9%) 
Comorbidity 
Yes 
No 
 
49 (87.5%) 
7 (12.5%) 
Ethnicity 
New Zealand European 
 
56 (100%) 
 
The most common comorbidities in the sample included arthritis (N=8), irritable 
bowel syndrome (N=8) chronic fatigue syndrome (N=7), heart disease (N=4) and 
migraines (N=4). The most common medications taken included paracetamol, 
codeine, ibuprofen, prednisone and gabapentin. 
The most frequent symptoms reported by FMS participants to be severe were; fatigue, 
somatic pain, sleep problems, and concentration difficulties. There were significantly 
higher rates of symptoms in the FMS sample on each of the 14 domains, in 
comparison to the community norms, with the exception of depression, compulsions 
and obsessions (see Table 2). 
 
Table 2. Percentage of participants scoring ≥2 on domains of the CIS-R 
 
Symptom domain NZ FMS female 
population N=56 
General female 
population N=472840 
Odds ratio (95% CI) Chi-squared 
Somatic pain 48% 8% 10.62 (4.67–24.15) 39.68** 
Fatigue 88% 32% 15.58 (7.47–32.50) 65.33** 
Concentration/forgetfulness 57% 11% 10.73 (5.11–22.50) 47.15** 
Sleep problems 77% 34% 6.50 (3.49–12.12) 37.43** 
Irritability 50% 22% 3.55 (1.92–6.55) 17.01** 
Worry about physical 
health 
29% 7% 5.43 (2.25–13.10) 16.40 ** 
Depression 16% 12% 1.40 (0.62–3.13) 66.40 n.s. 
Depressive ideas 30% 11% 3.47 (1.62–7.40) 11.08** 
Worry 43% 21% 2.84 (1.52–5.29) 11.12 ** 
Anxiety 25% 9% 3.37 (1.48–7.67) 9.07** 
Phobias 18% 6% 3.44 (1.30–9.07) 6.82** 
Panic 7% 2% 3.69 (0.75–18.21) 2.91** 
Compulsions 9% 4% 2.37 (0.71–7.98) 2.06 n.s. 
Obsessions 13% 7% 1.99 (0.76–5.21) 2.00 n.s. 
** p<0.01; n.s. = non-significant. 
 
The mean total score on the CIS-R for the FMS population was 16.52 (SD 8.19) with 
N=40 (71.43%) receiving a total score of >12.  
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Participants who were taking medication revealed a higher total mean score than those 
who were not medication (16.73, SD 8.50 and 14.40, SD 3.65 respectively), although 
this difference did not reach statistical significance, U = 109.50, p = 0.62. Exploring 
the effect of comorbidity on the symptom profile, there were also no significant 
differences between those with and without comorbid conditions on the total 
symptom score, U = 94.00, p = 0.06.  
The only significant difference observed on the subscale scores of the CIS-R was that 
those with a comorbid condition scored significantly higher on the fatigue subscale in 
comparison to those with no comorbid condition U = 84.50, p = 0.01.  
 
Table 3. Correlations between age, length of illness and subscales of the CIS-R 
 
 Age 
 
Len Som Fat Con Irr Wph Dep Di Wor Anx Pho Pan Com Obs 
Len .18               
Som -.37 .56              
Fat -.08 .14 -.05             
Con -.47 .10 .31 .17            
Sle .03 .02 .17 .27 -.05           
Irr -.36 -.07 .26 .14 .35           
Wph -.17 -.12 .08 .13 .49 .21          
Dep -.18 -.03 .08 .21 .44 .14 .40         
Di -.26* -.04 .06 .30 .37 .02 .40 .89        
Wor -.24 .08 .25 .04 .40 .25 .48 .47 .54       
Anx .02 -.24 -.06 .07 .11 .15 .47 .11 .09 .30      
Pho -.22 -.05 .23 .07 .38 .17 .43 .23 .34 .53 .27     
Pan .04 .22 .21 .20 .26 -.01 .26 .18 .24 .34 .38 .45    
Com -.20 -.14 .19 .02 .25 .08 .11 .17 .17 .12 .07 .04 .13   
Obs -.17 -.28 .23 .09 .12 .11 .02 .11 .07 -.01 -.13 .26 -.12 .21  
Tot -.45 -.06 .46 .31 .65 .40 .64 .62 .65 .70 .37 .65 .39 .25 .27 
 
Shading indicates that correlation is significant at the 0.01 level (2-tailed).  
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All significant correlations are shown in Table 3. Length of illness did not correlate 
with any of the variables and sleep only correlated with fatigue. As can be seen in 
Table 3. younger age was associated with more frequent and severe total symptoms 
and higher scores on the somatic symptoms, concentration difficulties, depressive 
ideas and irritability subscales. All subscales were associated with the total symptom 
score with the exception of the sleep and compulsions subscales. The relationship 
between age and the total CIS-R score is shown in Figure 1. 
 
 
 
Discussion 
This study aimed to explore the symptom profile of females with FMS in NZ using a 
structured clinical interview schedule. This study revealed that the most frequent and 
severe symptoms were fatigue, somatic pain, sleep and concentration difficulties. 
Significantly higher rates of symptoms were revealed in women with FMS on each of 
the subscales (with the exception of depression, compulsions and obsessions) and the 
total score, in comparison to community norms. The high frequency and severity of a 
wide range of symptoms in this sample of females with FMS highlights the need for 
clinical interventions to focus on addressing a range of symptoms in addition to pain.  
Although medication use revealed no significant effect on the findings of this study, 
this may be due to the low numbers of participants who were not taking medication. 
Participants with a comorbid condition revealed higher levels of fatigue and total 
symptom scores than those without. This was to be expected with participants 
reporting comorbid conditions, such as arthritis, chronic fatigue syndrome and heart 
disease however, this highlights the need to consider the occurrence of comorbid 
conditions when assessing symptoms in FMS. 
It was revealed that younger age was significantly associated with higher scores on 
somatic pain symptoms, concentration difficulties, irritability and depressive ideas 
sub-scales and also for the total score. Unexpectedly total symptom scores continued 
to decline into older age, when women were more likely to have comorbid conditions 
that may affect their scores. The negative correlation between age and FMS symptom 
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severity is similar to the results revealed in a previous study in FMS41 and may reflect 
either the acute phase of symptom onset, that people learn to manage their symptoms 
more effectively or that symptoms may improve over time.  
It was interesting to note that the sleep problems and compulsions subscales were not 
significantly associated with the total symptom score. This may suggest that the scales 
are measuring separate domains. Evidence has revealed that sleep is associated with 
physical outcomes such as pain and fatigue in FMS,41 However, previous studies have 
focused on the components of sleep quality rather than exploring sleep as one 
symptom domain as in the CIS-R.  
This study did not aim to explore the complexities of sleep quality in this population, 
but to explore generic perceived sleep disturbance in comparison to other symptoms 
of FMS and these results may therefore reflect a measurement issue. Few women with 
FMS reported experiencing compulsive symptoms in the previous month and these 
findings for the compulsions subscale may reflect the low variance for this variable.  
In contrast to previous findings, where levels of clinically significant depressive 
symptoms have been found to be high (approximately 83%),23 low levels of anxiety 
and depression were revealed in this study. Comparisons of the findings to 
community norms (which revealed no significant differences between females with 
FMS and the general population on levels of depression), suggests that depression is a 
more general public health issue than one specific to FMS.  
Studies looking specifically at levels of depression and anxiety in FMS have revealed 
inconsistent findings and may reflect differences between the populations studied, 
(e.g. hospital or community based), the measurements used (such as focusing on 
depression levels or depressive disorders as well as lifetime experience or current 
experience of depression) and the type of comparison groups used (e.g. general 
population norms and chronic pain controls). This may also support the proposal that 
depression is a consequence of chronic pain42 rather than a direct symptom of the 
FMS.  
The aim of the study was to recruit a sample that would be broadly representative of 
the NZ FMS population, however the ethnicity of the participants in this study was 
100% NZ European which limits the generalisability of the findings and the observed 
prevalence of symptoms should be considered with some caution. Studies exploring 
the impact and symptom experience of FMS for Māori are needed. 
The findings in this study are limited as they do not reflect the variability in the 
symptom experience over time. Participants often commented when completing the 
interview that their responses to the question would change according to the time of 
day or the activities that they had recently been engaged in.  
People with FMS frequently describe that their symptoms vary over the course of a 
day, with greater levels of pain and fatigue in the late afternoon/evening.43 Although 
the study was powered to detect significant differences between the FMS participants 
and normative data, the sample size is relatively small, did not include males with 
FMS and the possibility of random error in the findings cannot be excluded.  
It should also be noted that the community norms used as a comparison for this study 
were taken from a study conducted in the UK, rather than in NZ and therefore may 
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not truly represent the existence of common symptoms in the NZ community. These 
limitations may be reflected in the wide confidence intervals found in this study. The 
wide intervals could also highlight the wide variation in the symptom experience and 
it is likely that sub-groups of FMS may exist,7,44 emphasising the need to assess and 
treat the individual symptom experience in FMS.  
Despite the limitations of the study, the results reveal that consideration needs to be 
given to addressing a wider range of FMS symptoms in clinical practice, with a 
particular focus given to levels of fatigue, sleep problems and concentration 
difficulties. in order to meet patients needs,  
Since the completion of this study, the ACR diagnostic criteria have been revised to 
include a wider range of symptoms45. The findings of this study support the inclusion 
of a symptom impact scale into the criteria, particularly as the scale focuses on the 
three symptoms (fatigue, cognitive symptoms and feeling un-refreshed on awakening 
which is linked to sleep disturbance) found to be most problematic for women with 
FMS in this study.44,45 
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